AI could create the next life-saving drug.
Pharma players are already using AI to understand viral structures, identify small molecule drug candidates, and design novel proteins. They’re also embracing the technology as a way to streamline clinical trials, from patient recruitment to protocol design.
The space has seen a flurry of investment activity and consolidation this year. Biopharma player Recursion, for instance, acquired 2 startups — Cyclica and Valence — to boost its generative AI capabilities, while XtalPi, which applies AI to small molecule drug discovery, announced a partnership with Merck and a $250M deal with Eli Lilly.
Using CB Insights data, we identified 154 AI companies across 14 tech markets — from real-world data to biomedical NLP — helping pharma companies transform drug discovery and clinical trials.
Want to see more research? Join a demo of the CB Insights platform.
If you’re already a customer, log in here.
